- Home
- HUIZ vs LEXX Comparison
HUIZ vs LEXX Comparison
Compare HUIZ & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUIZ
- LEXX
- Stock Information
- Founded
- HUIZ 2006
- LEXX 2004
- Country
- HUIZ China
- LEXX Canada
- Employees
- HUIZ N/A
- LEXX N/A
- Industry
- HUIZ Specialty Insurers
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- HUIZ Finance
- LEXX Health Care
- Exchange
- HUIZ Nasdaq
- LEXX Nasdaq
- Market Cap
- HUIZ 20.8M
- LEXX 17.2M
- IPO Year
- HUIZ 2020
- LEXX N/A
- Fundamental
- Price
- HUIZ $2.31
- LEXX $0.85
- Analyst Decision
- HUIZ Hold
- LEXX Strong Buy
- Analyst Count
- HUIZ 1
- LEXX 1
- Target Price
- HUIZ $2.30
- LEXX $4.00
- AVG Volume (30 Days)
- HUIZ 24.1K
- LEXX 203.8K
- Earning Date
- HUIZ 09-24-2025
- LEXX 07-14-2025
- Dividend Yield
- HUIZ N/A
- LEXX N/A
- EPS Growth
- HUIZ N/A
- LEXX N/A
- EPS
- HUIZ N/A
- LEXX N/A
- Revenue
- HUIZ $168,454,627.00
- LEXX $615,923.00
- Revenue This Year
- HUIZ $11.94
- LEXX $38.85
- Revenue Next Year
- HUIZ $8.15
- LEXX $24.13
- P/E Ratio
- HUIZ N/A
- LEXX N/A
- Revenue Growth
- HUIZ 1.28
- LEXX 49.85
- 52 Week Low
- HUIZ $1.50
- LEXX $0.79
- 52 Week High
- HUIZ $10.58
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- HUIZ 47.71
- LEXX 41.87
- Support Level
- HUIZ $2.19
- LEXX $0.82
- Resistance Level
- HUIZ $2.76
- LEXX $1.05
- Average True Range (ATR)
- HUIZ 0.18
- LEXX 0.06
- MACD
- HUIZ -0.04
- LEXX -0.01
- Stochastic Oscillator
- HUIZ 23.49
- LEXX 11.44
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.